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OBJECTIVES We sought to investigate whether microalbuminuria, a proposed marker of generalized
vascular damage, enhances the prognostic value of ST-T segment changes for all-cause and
cardiovascular mortality in the general population.
BACKGROUND ST-T segment changes on the rest electrocardiogram (ECG) predict mortality in the general
population. However, the excess risk seems to be low, particularly in nonhospitalized
populations with a low cardiovascular risk profile.
METHODS In a population of 7,330 male and female subjects, a total of 89 deaths (1.2%) occurred during
a median three-year follow-up. In 69 of these, the cause of death was obtained from the
Central Bureau of Statistics: 25 subjects died of cardiovascular causes (36%). Using
computerized Minnesota coding, ST-T segment changes were coded as 4.1-4 and 5.1-4.
Microalbuminuria was defined as a urinary albumin excretion of 30 to 300 mg per 24 h.
RESULTS The combination of ST-T segment changes and microalbuminuria showed a higher hazard
ratio (HR) for all-cause mortality (HR 8.6 [95% confidence interval [CI] 4.8 to 15.2, p 
0.0001), as compared with ST-T segment changes in the absence of microalbuminuria (HR
1.3 [95% CI 0.7 to 2.5]), which was independent of other cardiovascular risk factors (HR 3.3
[95% CI 1.5 to 7.1], p  0.002). The combination showed a higher HR when only
cardiovascular deaths were taken into account, as compared with all-cause mortality (HR 24.5
[95% CI 7.9 to 76.0], p 0.0001), which also counted for ST-T segment changes alone (HR
4.4 [95% CI 1.4 to 14.5], p  0.02). After controlling for other risk factors, the HRs were
10.4 (95% CI 2.5 to 43.6, p  0.001) for the combination and 2.7 (95% CI 0.6 to 12.3) for
ST-T segment changes alone.
CONCLUSIONS This study suggests that, in subjects with ST-T segment changes on their rest ECG,
microalbuminuria could identify those at increased risk of all-cause and cardiovascular
mortality. (J Am Coll Cardiol 2002;40:1401–7) © 2002 by the American College of
Cardiology Foundation
The rest electrocardiogram (ECG) is a useful tool to
identify subjects at increased cardiovascular risk in the
general population (1,2). ST segment and T wave (ST-T)
changes, suggestive of myocardial ischemia, are associated
with an increased risk of total and cardiovascular mortality
(3,4). However, in a number of cases, particularly in
low-risk populations, these ST-T segment changes on the
rest ECG are not specific for coronary artery disease (5).
Therefore, additional easy-to-obtain markers of (subclini-
cal) cardiovascular disease are mandatory to improve cardio-
vascular risk profiling.
Microalbuminuria, usually diagnosed when there is a
urinary albumin excretion of 30 to 300 mg per 24 h (6), has
been hypothesized to be an indicator of generalized vascular
dysfunction (7). In diabetic as well as nondiabetic popula-
tions, microalbuminuria has been demonstrated to predict
cardiovascular disease, independent of traditional cardiovas-
cular risk factors (8,9). Moreover, we previously found in the
Prevention of REnal and Vascular ENd-stage Disease
(PREVEND) study that microalbuminuria was indepen-
dently associated with ischemic ECG abnormalities (10).
Therefore, microalbuminuria might identify subjects at
particular risk of ischemic heart disease and to enhance the
utility of ECG testing.
We hypothesized that microalbuminuria improves the
prognostic value of ECG markers suggestive of myocardial
ischemia. Therefore, we assessed the prognostic value of
ST-T segment changes on the rest ECG, taking the
presence of microalbuminuria into account, for all-cause
and cardiovascular mortality in the population at large.
METHODS
Study design and population. The population analyzed in
this study was obtained from the PREVEND study. The
PREVEND study was designed to investigate the natural
course of microalbuminuria and its relation to renal and
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cardiovascular disease in the general population. The study
cohort included male and female inhabitants, aged 28 to 75
years, of the city of Groningen, the Netherlands (11). These
inhabitants were asked to send in a morning urine sample.
A sample population consisting of all subjects with an
albumin concentration of 10 mg/l in the morning urine
sample, completed with a randomly selected sample of the
remainder of the population (morning urine albumin excre-
tion 10 mg/l), made two visits to an outpatient clinic.
Subjects using insulin or those who were pregnant were
excluded. The visits consisted of anthropometric measure-
ments, blood pressure measurements for 10 min with an
automatic Dinamap XL model 9300 series device (Johnson-
Johnson Medical Inc., Tampa, Florida), collection of two
24-h urine samples, ECG recording, and obtainment of
fasting blood samples. Furthermore, all participants com-
pleted a questionnaire on demographic data and cardiovas-
cular and renal history. Because the objective of this study
was to assess risk factors for cardiovascular end-stage dis-
ease, all analyses were performed after excluding subjects
with clinical or ECG evidence, defined by Minnesota codes
1.1 and 1.2, of a previous myocardial infarction.
A total of 8,592 subjects made two visits to the outpatient
clinic. For the present study, 18 subjects were excluded
because of missing albuminuria data, 433 because of the
presence of hematuria or leukocyturia, 117 because of
macroalbuminuria, and 70 because of missing ECG data.
At the outpatient clinic, two participants appeared to use
insulin and were excluded. Furthermore, 622 subjects were
diagnosed with a previous myocardial infarction and were
also excluded. Finally, 7,330 subjects were eligible for
analysis. The median follow-up period was 987 days (range
2 to 1,229). During the follow-up period, 89 deaths (1.2%)
occurred. In 69 of these, the cause of death was obtained
from the Central Bureau of Statistics: 25 subjects died of
cardiovascular causes (36%).
All participants gave written, informed consent. The
PREVEND study was approved by the local medical Ethics
Committee and conducted in accordance with the guide-
lines of the Declaration of Helsinki.
Mortality data. The vital status was checked through the
municipal register. Mortality follow-up was initiated in
September 1997 and followed until February 2001. The
cause of death was obtained by linking the number of the
death certificate to the primary cause of death, as coded by
a physician of the Central Bureau of Statistics. Causes of
death were coded according to the tenth revision of the
International Classification of Diseases (ICD-10). Cause-
specific end points used in the analyses were all-cause
mortality (ICD A00-Y89) and cardiovascular mortality
(ICD I00-I99). In the analyses of specific causes of death,
follow-up information until September 2000 was used. The
census date was the date on which the information was
obtained from the municipal registry (for the living) or the
date of death. If a person had moved to an unknown
destination, the date on which the person was dropped from
the municipal registry was used as the census date.
Laboratory methods. Urinary volume and albumin were
measured in each collection. Urinary albumin concentra-
tions were determined by nephelometry with a threshold of
2.3 mg/l and intra-assay and inter-assay coefficients of
variation of 4.3% and 4.4%, respectively (Dade Behring
Diagnostic, Marburg, Germany). Leukocyte and erythrocyte
counts were determined by urine sticks (Nephurleuco,
Boehringer Mannheim, Mannheim, Germany). Serum glu-
cose and serum cholesterol were determined by Kodak
Ektachem dry chemistry (Eastman Kodak, Rochester, New
York).
Electrocardiography. Standard 12-lead ECGs were re-
corded with Cardio Perfect equipment (Cardio Control,
Delft, The Netherlands), stored digitally, and classified
according to the Minnesota code, using the computer
program MEANS (Modular ECG Analysis System)
(12,13). Signal analysis and classification of MEANS have
been extensively evaluated in both clinical and general
population samples (14). Results show that the program is
as good as or better than the human reader for sensitivity
and specificity of all Minnesota Code categories (12). The
sensitivity for ST segment depression was 96.0% for visual
coding and 96.8% for computer coding, whereas the spec-
ificity was 98.3% and 99.4%, respectively. For T wave items,
the sensitivity was 98.3% for visual coding and 96.0% for
computer coding, whereas the specificity was 93.5 and 99.2,
respectively. ST-T segment changes were defined by Min-
nesota codes 4.1-4 and 5.1-4 (3).
Definitions. The urinary albumin excretion rate was mea-
sured as the mean of two 24-h urine collections, and
microalbuminuria was diagnosed at 30 to 300 mg per 24 h.
Albumin measurements were considered unreliable when
75 leukocytes per l or 50 erythrocytes per l were
measured in the urine. Conventional cardiovascular risk
indicators were: age 60 years, male gender, hypertension
(diastolic blood pressure 90 mm Hg or systolic blood
pressure 140 mm Hg or current antihypertensive treat-
ment), hypercholesterolemia (total serum cholesterol 6.5
mmol/l or the use of lipid-lowering medication), diabetes
mellitus (fasting plasma glucose levels 7.0 mmol/l or
nonfasting glucose 11.1 mmol/l [5.2% of the study pop-
ulation was not fasting] or the use of antidiabetic drugs),
overweight (body mass index 27 kg/m2), cardiovascular
family history (first-grade relatives had established a cardio-
vascular event before 55 years of age), and smoking (stopped
smoking less than a year ago or current cigarette smoking).
Abbreviations and Acronyms
CI  confidence interval
ECG  electrocardiogram
HR  hazard ratio
PREVEND  Prevention of REnal and Vascular ENd-
stage Disease study
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Statistical analysis. To evaluate the effect of ST-T seg-
ment changes with or without microalbuminuria, four
groups were created. The first group, which served as the
reference group, consisted of subjects with no ST-T seg-
ment changes and no microalbuminuria; the second group
of subjects had no ST-T segment changes and present
microalbuminuria; the third group of subjects had ST-T
segment changes and no microalbuminuria; and the fourth
group of subjects had both ST-T segment changes and
microalbuminuria. Survival was estimated by the Kaplan-
Meier product-limit method, compared with the log-rank
test, and stratified for the four groups. This was performed
separately for survival free of all-cause mortality and cardio-
vascular mortality. All-cause and cardiovascular mortality
risks and 95% confidence intervals (CIs) were estimated
with Cox proportional hazards regression analysis. In the
case of cardiovascular mortality, patients who died of causes
other than coronary heart disease were censored at the time
of their death. The assumption of proportional hazards was
checked by complementary log plots. Relative hazard ratios
(HRs) for each specific co-variate of the final models were
computed as the exponential of the regression coefficient.
The contribution of two-factor interactions with the model
was evaluated for variables that showed significant (p 
0.05) main effects. Three different models were used: model
1 was unadjusted; model 2 was adjusted for age 60 and
male gender; and model 3 was adjusted for age 60, male
gender, and established cardiovascular risk factors (e.g.,
hypertension, hypercholesterolemia, diabetes mellitus, over-
weight, cardiovascular family history, smoking). A two-
sided p value of 0.05 was considered statistically signifi-
cant. Analyses were performed using the statistical package
SPSS version 9.0 (Chicago, Illinois).
RESULTS
The prevalence of all ST-T segment changes together was
16.9%. The prevalence of more severe ST-T segment
changes (codes 4.1-2 and 5.1-2) was 7%, whereas that for
less severe ST-T segment changes (codes 4.3-4 and 5.3-4)
was 9.9%. The baseline characteristics of the total popula-
tion and those stratified by ST-T segment changes and
microalbuminuria are listed in Table 1. Microalbuminuria
identifies subjects with an increased cardiovascular risk,
particularly in combination with ST-T segment changes.
Subjects with microalbuminuria and ST-T segment changes
were older and more often male and had a high prevalence
of hypertension, hypercholesterolemia, obesity, and diabetes
mellitus. Smoking and cardiovascular family history was
approximately equal among the four groups.
Table 2 shows the incidence of all-cause and cardiovas-
cular mortality. Both were low in the group with no ST-T
segment changes and no microalbuminuria, and highest in
the group with both ST-T segment changes and microalbu-
minuria.
The overall relative risk of total mortality associated with
ST-T segment changes in the population was 2.1 (unad-
justed; 95% CI 1.4 to 3.3, p  0.001) and 1.3 (adjusted for
cardiovascular risk factors; 95% CI 0.7 to 2.2, p  0.4),
whereas the overall relative risk of microalbuminuria was 4.3
(unadjusted; 95% CI 2.8 to 6.6, p  0.001) and 2.3
(adjusted; 95% CI 1.3 to 4.1, p  0.004). Figure 1 shows
Kaplan-Meier survival curves with respect to all-cause and
cardiovascular mortality in the four groups. Log-rank sta-
Table 1. Baseline Characteristics
No ST-T Segment
Changes/
No Microalbuminuria
(n  5,424 [74%])
No ST-T Segment
Changes/
Microalbuminuria
(n  662 [9%])
ST-T Segment
Changes/
No Microalbuminuria
(n  1,021 [14%])
ST-T Segment
Changes/
Microalbuminuria
(n  223 [3%])
Total
(n  7,330)
Age (yrs) 47  12 53  12 51  13 59  12† 48  12
Gender (male) 48% 62% 49% 69† 50%
Urinary albumin excretion (mg/24 h)* 8.0 (5.9–12.0) 52.4 (37.8–88.5) 8.8 (6.2–13.1) 55.3 (39.8–86.0)† 8.9 (6.2–15.9)
Diastolic blood pressure (mm Hg) 73  9 78  10 75  10 83  12† 74  10
Systolic blood pressure (mm Hg) 125  17 139  22 133  22 153  24† 128  20
Hypertension 23% 53% 39% 78† 29%
Cholesterol (mmol/liter) 5.6  1.1 5.9  1.2 5.7  1.1 5.9  1.1† 5.6  1.1
Hypercholesterolemia 22% 32% 26% 35† 24%
Body mass index (kg/m2) 25.7  4.0 27.7  4.9 25.7  4.1 28.1  4.6† 26.0
Overweight 32% 51% 33% 59† 35%
Glucose (mmol/liter) 4.7  0.9 5.4  1.9 4.9  1.2 5.7  2.4† 4.9  1.1
Diabetes mellitus 2% 10% 4% 11† 3%
Smoking 39% 42% 34% 36% 38%
Cardiovascular family history 22% 26% 24% 20% 22%
*Median value (25th–75th percentile). †p  0.001 for trend. Continuous variables are given as the mean value  SD.
Table 2. Incidence of Deaths From Any Cause (A) and
Cardiovascular Causes (B)
A Microalbuminuria
No
Microalbuminuria
ST-T segment changes 16 (7.2%) 11 (1.1%)
No ST-T segment changes 17 (2.6%) 45 (0.8%)
B Microalbuminuria
No
Microalbuminuria
ST-T segment changes 6 (2.7%) 5 (0.5%)
No ST-T segment changes 8 (1.3%) 6 (0.1%)
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tistics were highly significant for both all-cause and cardio-
vascular mortality (p  0.001). The significance of the
differences in all-cause and cardiovascular mortality risk
among the four groups was tested by Cox regression
analysis, using the group with no ST-T segment changes
and no microalbuminuria as the reference group (Table 3).
The combination of ST-T segment changes and microalbu-
minuria showed the highest HR for all-cause mortality,
which was independent of other cardiovascular risk factors.
In addition, microalbuminuria alone was predictive of all-
cause mortality, although it was not independent of the
other risk factors. ST-T segment changes did not signifi-
cantly predict all-cause mortality. The combination showed
a higher HR when only cardiovascular deaths were taken
into account, as compared with all-cause mortality, which
also counted for microalbuminuria alone. ST-T segment
changes in the absence of microalbuminuria were predictive
of cardiovascular mortality. However, this was not indepen-
dent of other risk factors.
We also explored the additional impact of classic cardio-
vascular risk factors related to ST-T segment changes on
mortality (Fig. 2). This demonstrated that the combination
of ST-T segment changes and microalbuminuria had the
highest predictive value for mortality.
DISCUSSION
This study demonstrates that in a nonhospitalized popula-
tion, microalbuminuria increases the mortality risk associ-
ated with ST-T segment changes on the rest ECG. The
effect is independent of cardiovascular risk factors and seems
even greater for cardiovascular mortality. The additive value
of microalbuminuria to ST-T segment changes was higher
Figure 1. Kaplan-Meier estimates of all-cause (A) and cardiovascular (B) mortality in the four groups.
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than that of established cardiovascular risk factors, such as
hypertension and hypercholesterolemia.
The ECG can be used to determine the presence of
ischemic heart disease in a population at large (10). In three
Chicago-based epidemiologic studies, ECG abnormalities,
particularly major abnormalities, were independently asso-
ciated with cardiovascular mortality and morbidity (15).
Also, both the Honolulu Heart Program and the Busselton
Study showed an independent contribution of major and
minor ECG abnormalities for coronary heart disease (1,2).
Furthermore, in the Framingham study, nonspecific ST
segment and T wave abnormalities on the rest ECG were
associated with an increased risk of cardiovascular disease
(16). These results have been validated in various other
epidemiologic studies for both men and women (4), as well
as for different races (17). However, the excess risk seems to
be small, particularly in nonhospitalized populations with a
low cardiovascular risk profile (5). Although ST-T segment
changes in subjects with a previous myocardial infarction are
associated with a 10-fold risk of coronary heart disease, the
risk was only twofold in subjects without known ischemic
heart disease (3). ST-T segment changes on the rest ECG
might be due to causes other than myocardial ischemia (e.g.,
hyperventilation, emotional strain, recent food ingestion) (18).
This limits the applicability of the rest ECG for screening
purposes in the population at large. Additional markers of
(subclinical) atherosclerotic disease may enhance stratification
for cardiovascular disease in order to adequately target preven-
tive strategies. For example, the combination of ST-T segment
changes and hypercholesterolemia did improve the identifica-
tion of male subjects at risk of coronary heart disease in the
West of Scotland Coronary Prevention study (19).
Table 3. Hazard Ratios (95% Confidence Intervals) for All-Cause and Cardiovascular Mortality Stratified by ST-T Segment Changes
and Microalbuminuria
All-Cause Mortality
Model 1* Model 2† Model 3‡
No ST-T segment changes/no microalbuminuria 1.0 1.0 1.0
No ST-T segment changes/microalbuminuria 3.1 (1.8–5.5) p  0.0001 2.0 (1.2–3.6) p  0.01 1.8 (0.9–3.6)
ST-T segment changes/no microalbuminuria 1.3 (0.7–2.5) 0.9 (0.5–1.8) 0.9 (0.4–1.9)
ST-T segment changes/microalbuminuria 8.6 (4.8–15.2) p  0.0001 3.9 (2.1–7.1) p  0.0001 3.3 (1.5–7.1) p  0.002
Cardiovascular Mortality
No ST-T segment changes/no microalbuminuria 1.0 1.0 1.0
No ST-T segment changes/microalbuminuria 11.0 (3.8–31.6) p  0.0001 7.1 (2.4–20.9) p  0.0004 4.5 (1.1–18.9) p  0.04
ST-T segment changes/no microalbuminuria 4.4 (1.4–14.5) p  0.01 3.3 (1.0–11.1) p  0.05 2.7 (0.6–12.3)
ST-T segment changes/microalbuminuria 24.5 (7.9–76.0) p  0.0001 11.1 (3.4–36.4) p  0.0001 10.4 (2.5–43.6) p  0.001
*Unadjusted. †Adjusted for age 60 years and male gender. ‡Adjusted for age 60 years, male gender, hypertension, hypercholesterolemia, overweight, diabetes mellitus,
cardiovascular family, history, and smoking.
Figure 2. Relative risk of the combination ST-T segment changes and cardiovascular risk indicators for all-cause mortality adjusted for age and gender.
1405JACC Vol. 40, No. 8, 2002 Diercks et al.
October 16, 2002:1401–7 ST-T Segment Changes and Microalbuminuria
The prognostic value of microalbuminuria for cardiovas-
cular disease was first established in patients with diabetes
mellitus (8). In nondiabetic subjects, the results from several
studies have indicated that microalbuminuria is a marker of
cardiovascular risk factors (11,20,21) and (subclinical) car-
diovascular disease (10,22). Moreover, several studies have
demonstrated that microalbuminuria is an independent
predictor of cardiovascular morbidity and mortality in non-
diabetic populations (9,23,24). In the present study, we
demonstrate a major increase in mortality in the subset of
subjects with both ST-T segment changes and microalbu-
minuria. It has been postulated that microalbuminuria
indicates increased vascular or endothelial permeability that
is not only restricted to renal vessels, which could promote
foam-cell formation and atherogenesis by increased leakage
of lipoprotein particles, for example, into the vessel wall (7).
An increased transcapillary albumin excretion rate (25), an
increased plasma level of von Willebrand factor (26), and an
attenuated endothelium-dependent response to vasodilator
stimuli (27) in subjects with microalbuminuria support this
hypothesis. Therefore, individuals with ST-T segment
changes in addition to microalbuminuria could be at in-
creased risk of enhanced progression of atherosclerosis and
subsequently mortality. Moreover, this hypothesis might
explain why microalbuminuria without ST-T segment
changes also predicts cardiovascular mortality.
A few limitations should be mentioned. First, only a
limited number of (cardiovascular) deaths were observed,
explaining the large confidence intervals of the HRs. More-
over, in 20 subjects, we did not have information on the
cause of death. Therefore, we should be cautious not to
overemphasize the predictive value of the combination of
ST-T segment changes and microalbuminuria, particularly
on cardiovascular mortality. Second, the relatively short
follow-up period could explain the fact that ST-T segment
changes did not independently predict mortality, in contrast
to the results from studies with a longer follow-up period.
Conclusions. This study shows that, in subjects with ST-T
segment changes on their rest ECG, microalbuminuria may
identify those at increased risk of all-cause and cardiovascular
mortality. This suggests that ST-T segment changes reflect
ischemic cardiac disease, particularly in the presence of other
signs of generalized vascular damage. Therefore, measurement
of urinary albumin excretion might improve cardiovascular risk
profiling in the population at large, particularly in subjects with
ECG signs of ischemic heart disease. However, the findings of
this study need to be confirmed, and the added value of
microalbuminuria to conventional cardiovascular risk factors
needs to be further established before microalbuminuria can be
incorporated into clinical practice.
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